Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19

Serological responses to spike antigens following SARS-CoV-2 infection

We recruited a cross-sectional cohort (N=41) of Australian adults recovered from mild-moderate SARS-CoV-2 infection and isolated plasma and PBMC samples at a median of 32 (IQR: 28-35) days post-positive PCR test. The cohort had a median age of 59 (IQR: 54-65) and was 43% female (17 of 41). Subjects reported mild to moderate upper and lower respiratory tract symptoms with only 5 (12%) requiring hospitalisation, and none requiring mechanical ventilation (Table S1). A control cohort of 27 healthy adults was recruited prior to widespread infection in Australia (Table S2). As we had an interest in the degree to which baseline cross-reactive coronavirus immunity affected SARS-CoV-2 responses, we pre-screened the 27 uninfected subjects for serological reactivity against the beta coronavirus HCoV-HKU1 (HKU1) (Figure S1), selecting individuals with the 5 highest and 5 lowest plasma titres as controls for the study.

Serological profiles are presented stratified across the cohort based on neutralisation activity for each subject. Antibodies binding the SARS-CoV-2 spike (Figure 1A) or the RBD (Figure 1B) were consistently observed in all 41 infected individuals by ELISA, with minimal reactivity in the controls. Titres of S- and RBD-specific antibody were highly correlated (Figure S2). Consistent with previous reports ¹⁸, low-level antibody responses cross-recognising the SARS-CoV RBD were observed in most of our SARS-CoV-2 infected cohort (Figure 1C). Antibody responses to the human coronavirus strain HKU were prevalent at moderate to high levels across the cohort, in line with previous reports of widespread seropositivity to S proteins of human coronaviruses in adults ^19,20 (Figure 1D). The capacity of immune plasma to block interaction between recombinant ACE2 and RBD was assessed by ELISA, with modest levels of inhibition detected in most subjects, and selected subjects exhibiting potent inhibitory activity (Figure 1E). Virus neutralising activity in the plasma was similarly assessed using a microneutralisation assay with live SARS-CoV-2 infection of Vero cells as previously described for SARS-CoV and MERS-CoV^21,22. Neutralising antibody titres ranged from 40 to 508 (IQR:113-254) (Figure 1F). In summary, antibody responses against both S and the RBD are consistently elicited in SARS-CoV-2 infected individuals, the endpoints titres of which correlate significantly with neutralising activity (r=0.55 and r=0.61 respectively) and ACE2 binding inhibition (r=0.72 and r=0.72 respectively) in the plasma (Figure S2).

• Download figure
• Open in new tab

Figure 1. Serological responses to COVID19

Plasma samples from subjects recovered from SARS-CoV-2 infection (N=41) and healthy controls (N=10, black/grey bars) were screened by ELISA for reactivity against S recombinant proteins from (A) SARS-CoV-2 S, (B) SARS-CoV-2 RBD, (C) SARS-CoV RBD and (D) HCoV-HKU1. (E) The capacity of plasma antibodies to inhibit the interaction of RBD with human ACE2 was tested in an ELISA format at a plasma dilution of 1:25. (F) Neutralisation activity in the plasma was assessed using a microneutralisation assay. Data represent individual responses for each subject, and column order for all figures is conserved and stratified on the basis of plasma neutralisation activity. SARS-CoV-2 negative donors were stratified based on HCoV-HKU1 serological titres (black, high titres; grey, low titres).

B cell responses to S antigens following SARS-CoV-2 infection

We next examined the frequency and specificity of class-switched B cells in convalescent subjects using SARS-CoV-2 spike or RBD proteins as flow cytometric probes. Clear antigen-specific populations of CD19⁺IgD⁻ B cells (gating in Figure S3) binding spike, spike and RBD or RBD alone could be resolved in our cohort of recovered from SARS-CoV-2 subjects, with minimal background staining in uninfected controls (Figure 2A; Figure S4). Frequencies of spike⁺RBD⁻, spike⁺RBD⁺ and spike⁻RBD⁺ B cells as a proportion of the CD19⁺IgD⁻ population were a median 0.38% (IQR 0.24-0.52), 0.047% (IQR 0.023-0.084) and 0.033% (IQR 0.015-0.045), respectively (Figure 2B). The very low frequencies of spike⁻RBD⁺ B cells likely constitute a mix of background staining and B cells that recognise RBD epitopes occluded in recombinant S or intact virus. Immunoglobulin isotypes were determined for spike⁺RBD⁻ and spike⁺RBD⁺ populations using IgM and IgG surface staining, with IgM⁻IgG⁻ class-switched B cells previously established to be almost exclusively IgA^{+ 23}. In our cohort sampled a median of 36 days after symptom onset, the majority of spike⁺RBD⁻ class-switched B cells were IgG⁺ (median 57.5%; IQR 46.8-64.8), with smaller proportions displaying IgM⁺ (20.9%; IQR 17.4-29.1) and IgA⁺ (IgM⁻IgG⁻) (17.4%; IQR 13.2-25.9) (Figure 2C). Isotype distribution of spike⁺RBD⁺ B cells was more variable due to low event counts, with median frequencies of 45.5% (IQR 27.8-70.7) IgG, 13.6% (IQR 0-30.3) IgM and 20.0% IgA (IQR 4.73-41.9). The activation phenotype of antigen-specific B cells was assessed using CD21 and CD27 surface staining²⁴(Figure S5). Most spike⁺RBD⁻ (median 58.5%; IQR 52.2-66.6) or spike⁺RBD⁺ (68.7%; IQR 54.4-80) class-switched B cells displayed a resting memory phenotype (CD21⁺CD27⁺), also consistent with the median duration of infection. However, a significant proportion of activated memory B cells (CD21 ⁻CD27⁺) was still evident for both spike⁺RBD⁻ (18.9%; IQR 13.2-25.7) or spike⁺RBD⁺ B cell populations (13.2%; IQR 5.88-20), with only low proportions of CD21⁻CD27⁻ and CD21⁺CD27⁻ phenotypes observed. Overall, SARS-CoV-2 infection efficiently elicits both S- and RBD-specific B cells in most subjects after recovery, which constitute a significant proportion of the memory B cell pool, which are mostly IgG⁺ and of a resting memory phenotype.

• Download figure
• Open in new tab

Figure 2. Frequency and phenotype of SARS-CoV-2-specific B cells following infection

(A) Co-staining class-switched B cells (CD19⁺IgD-) with SARS-CoV-2 spike and RBD probes allows resolution of antigen-specific cells in subjects previously infected with SARS-CoV-2 relative to uninfected controls. (B) Frequencies of spike⁺RBD⁻, spike⁺RBD⁺ and spike⁺RBD⁻ B cells as a proportion of CD19⁺IgD⁻ B cells in PBMC from subjects previously infected with SARS-CoV-2 (N=41) and uninfected controls (N=10). (C) Isotype distribution of spike⁺RBD⁻ and spike⁺RBD⁺ CD19⁺IgD⁻ B cells; n.d – not detected due to absent probe⁺ cells. (D) Co-staining spike⁺CD19⁺IgD⁻ B cells with SARS-CoV-2 and SARS-CoV RBD probes allows discrimination of cross-reactive specificities versus those unique to SARS-CoV-2. (E) Frequency of SARS-CoV-2 RBD⁺/SARS-CoV RBD⁻ cells as a proportion of spike⁺CD19⁺IgD-IgG⁺ B cells and their correlation (Spearman) to (F) ACE2/RBD binding inhibition and (G) neutralising activity in plasma.

The RBD of SARS-CoV and SARS-CoV-2 share significant homology, but with marked diversity within the ACE2 binding motif despite shared recognition of this cellular receptor ^2,25. We examined whether differential staining with SARS-CoV and SARS-CoV-2 probes would allow more precise identification of B cells recognising the unique ACE2 binding site of SARS-CoV-2, to understand why some individuals had notable RBD-specific antibody titres but with limited neutralisation activity or RBD/ACE2 binding inhibition. PBMCs from a subset of COVID⁺ subjects (N=15) were stained with SARS-CoV-2 spike, SARS-CoV-2 RBD and SARS-CoV RBD probes as before (Figure 2D). Both SARS-CoV-2 RBD-specific and SARS-CoV/SARS-CoV-2 cross-reactive IgG⁺ B cells could be resolved in most subjects (Figure S6), with cells binding only SARS-CoV-2 RBD making up the major fraction of the spike⁺RBD⁺ response (Figure 2E). However, while increased proportions of SARS-CoV-2 RBD-specific B cells within the spike⁺ response does broadly track with plasma blockade of RBD/ACE2 binding (Figure 2F; r=0.46), we find no correlation with neutralisation activity (Figure 2G: r=0.05).

CD4 T cell responses to S antigens following SARS-CoV-2 infection

TFH provide critical cognate help to antigen-specific B cells to initiate and maintain humoral immune responses ²⁶. Circulating TFH cells (cTFH; CD3⁺CD4⁺CD45RA⁻ CXCR5⁺, gating in Figure S7) in the blood provide a surrogate indication of TFH activity in lymphoid tissues ^27,28. Total unstimulated cTFH frequencies were similar across SARS-CoV-2 convalescent and uninfected donors (Figure S8). Antigen specificity of the cTFH population was determined using an activation induced marker (AIM) assay ²⁹ in response to stimulation with SARS-CoV-2 spike or RBD proteins (Figure 3A). Overall, recovered subjects exhibited robust cTFH responses to the SARS-CoV-2 spike protein, with a median of 0.92% spike-specific cTFH cells (IQR 0.42 – 1.52; Figure 3B). In contrast to the full spike, RBD-specific cTFH responses were significantly lower (p<0.0001), with a median of only 0.12% of cTFH cells exhibiting RBD specificity (IQR 0.04 – 0.38). Consistent with the high frequency of HKU1 seropositivity among the convalescent cohort (Figure 1D), cTFH responses to HKU1 spike were detected among 97.5% of donors (median 0.52% of cTFH cells, IQR 0.32 – 0.99). The frequency of HKU1-specific cTFH was generally higher among the convalescent cohort than the uninfected controls (Figure 3B), suggesting a boosting of cross-reactive T cell responses following SARS-CoV-2 infection.

• Download figure
• Open in new tab

Figure 3. Specificity of cTFH responses to coronavirus spike proteins

(A) Representative staining of CD25 and CD134 co-expression on cTFH (CD3⁺CD4⁺CD45RA⁻CXCR5⁺) cells following stimulation with 5μg/mL BSA (negative control), SARS-CoV-2 Spike, SARS-CoV-2 RBD or HCoV HKU1 protein, or SEB (positive control). (B) Antigen-specific cTFH (n=10 SARS-CoV-2 negative, n=41 SARS-CoV-2 positive donors) frequencies were calculated as the proportion of CD25⁺CD134⁺ cTFH cells in each stimulation condition after background subtraction using the negative control. (C) Representative expression of CCR6 and CXCR3 on bulk cTFH, SARS-CoV-2 Spike-specific, HCoV HKU1 Spike-specific or SEB-responsive (CD25⁺OX⁻40⁺) cTFH. (D) Quantification of CCR6⁺CXCR3⁻, CCR6⁺CXCR3⁺, CCR6⁻CXCR3⁺ or CCR6⁻CXCR3⁻ cTFH populations among SARS-CoV-2 positive donors (n=41).

cTFH populations have classically been divided on the basis of surface expression of chemokine receptors CCR6 and CXCR3 ^28,30,31. However the functional capacities and relevance of putative cTFH1 (CCR6⁻CXCR3⁺), cTFH2 (CCR6⁻CXCR3⁻) and TH17-like (CCR6⁺CXCR3⁻) cTFH subsets are still unclear and may be pathogen-dependent or vary with anatomical location ^27,28,31. In contrast to the total unstimulated cTFH population, SARS-CoV-2 spike and HKU-specific cTFH were enriched for CCR6⁺CXCR3⁻ cells (median 52.6% of SARS-CoV-2 spike-specific, 62.9% of HKU1 spike-specific or 21.1% of bulk cTFH, p<0.0001, Figure 3C/3D). Comparison to SEB-stimulated cells from a subset of donors confirmed that in vitro TCR stimulation does not preferentially activate or upregulate expression of CCR6 among the cTFH population (Figure 3D).

Analysis of spike-specific non-cTFH CD4 memory (CD3⁺CD4⁺CD45RA⁻CXCR5⁻) cells revealed similar patterns of antigen reactivity to the cTFH compartment; namely, strong recognition of SARS-CoV-2 and HKU1 spike proteins (median 0.53% and 0.54% of CD4 memory cells, respectively) and lower frequencies of RBD-specific T cells (median 0.24% of CD4 memory cells) (Figure S8).

Predictors of plasma neutralisation activity

The development of serological neutralisation activity will be a critical endpoint for upcoming SARS-CoV-2 vaccine trials. A co-correlation matrix of subject characteristics and immunological parameters was generated (Figure 4A). This analysis highlighted broad co-correlation of many immune parameters related to S immunogenicity, namely antibody titres and the circulating frequencies of S-specific B and T cell populations. Principal component analysis (PCA) on immunological variables revealed clustering of the cohort into subjects with stronger and weaker plasma neutralisation activity (Figure 4B). Using a multiple regression approach, we identified titres of S-specific antibody and the proportion of S-specific cTFH with a TH17-like phenotype (CCR6⁺CXCR3⁻) as the two most significant predictive factors related to neutralisation activity (Figure 4C).

• Download figure
• Open in new tab

Figure 4. Predictors of plasma neutralisation activity

(A) Co-correlation matrix of subject characteristics, infection and immunological dynamics in subjects recovered from SARS-CoV-2 infection. (B) Principle component analysis of immune parameters showing individuals coloured in proportion to plasma neutralization titres. (C) Spearman correlation of the plasma neutralisation activity with S-specific antibody titres and the proportion of CCR6⁺CXCR3⁻ phenotype with the S-specific cTFH population.

Ethics Statement

The study protocols were approved by the University of Melbourne Human Research Ethics Committee (#2056689) and all associated procedures were carried out in accordance with the approved guidelines. All participants provided written informed consent in accordance with the Declaration of Helsinki.

Subject recruitment and sample collection

Subjects who had recovered from COVID19 and healthy controls were recruited through contacts with the investigators and invited to provide a blood sample. Subject characteristics of SARS-CoV-2 convalescent subjects are collated in Table S1 and the healthy controls in Table S2. For all participants, whole blood was collected with sodium heparin anticoagulant. Plasma was collected and stored at −80°C, and PBMCs were isolated via Ficoll Paque separation, cryopreserved in 10% DMSO/FCS and stored in liquid nitrogen.

Expression of coronavirus proteins and hACE2

A set of proteins was generated for serological and flow cytometric assays. The ectodomain of SARS-CoV-2 (isolate WHU1;residues 1 – 1208) or HCoV-HKU1 S protein (isolate N5;residues 1 – 1290) were synthesised with furin cleavage site removed and P986/987 stabilisation mutations³⁹, a C-terminal T4 trimerisation domain, Avitag and His-tag, expressed in Expi293 cells and purified by Ni-NTA affinity and size-exclusion chromatography using a Superose 6 16/70 column (GE Healthcare) (Figure S9). SARS-CoV S was biotinylated using Bir-A (Avidity). The SARS-CoV-2 RBD⁴⁰ with a C-terminal His-tag (residues 319-541; kindly provided by Florian Krammer) was similarly expressed and purified. SARS-CoV RBD (residues N321-P513) with a C-terminal Avitag and His-tag, was expressed in Expi293 cells and purified by Ni-NTA, biotinylated using Bir-A (Avidity) and purified by ize-exclusion chromatography using a S-75 Superdex (GE Healthcare). The human (residues 19-613) and mouse (residues 19-615) ACE2 ectodomain with C-terminal His-tag (kindly provided by Merlin Thomas) were expressed in Expi293 cells and purified using Ni-NTA and size-exclusion chromatography (Figure S10). Antigenicity of coronaviral proteins was assessed by binding to immune sera, anti-RBD mAbs CR3022 and 4B, or human and mouse ACE2 (Figure S11). The glycosylation profile of recombinant S proteins (Figure S11) was assessed using mass spectrometry as previously described⁴¹ by SP3 protein clean up⁴² and trypsin in-solution digestion. Purified peptides were desalted then separated using a two-column chromatography set up comprising a PepMap100 C18 20 mm × 75 μm trap and a PepMap C18 500 mm × 75 μm analytical column on Dionex Ultimate 3000 UPLC (ThermoFisher). Samples were concentrated onto the trap column at 5 μl/min with Buffer A (2% acetonitrile, 0.1% formic acid) for 6 min and infused into a Q-Exactive™ plus mass spectrometry (ThermoFisher) at 300 nl/min via the analytical column. 125 min gradients were used altering the buffer composition from 2% Buffer B (80% acetonitrile, 0.1% formic acid) to 28% B over 95 min, then from 28% B to 40% B over 10 min, then from 40% B to 100% B over 2 min, the composition was held at 100% B for 3 min, and then dropped to 3% B over 5 min and held at 3% B for another 10 min. The Q-Exactive™ plus Mass Spectrometer was operated in a data-dependent mode automatically switching between the acquisition of a single Orbitrap MS1 scan (70,000 resolution, AGC of 3 × 10⁶) followed by 15 data-dependent HCD MS2 events (35,000 resolution; stepped NCE 28, 30, 32; maximum injection time of 125 ms and AGC of 2 × 10⁵) with 30 s dynamic exclusion enabled.

The identification of glycoforms were accomplished using Byonic [Protein Metrics, version 3.5.3⁴³. MS raw file were searched with a MS1 tolerance of ±5 ppm and a tolerance of ±20 ppm was allowed for HCD MS2 scans. Searches were performed using cysteine carbamidomethylation as a fixed modification, methionine oxidation as a variable modification in addition to allowing N-linked glycosylation on asparagine. The default Byonic N-linked glycan database, which is composed of 309 mammalian N-glycans compiled was used. The proteases specificity was set to full trypsin specificity and a maximum of two miss-cleavage events allowed. Data searched against the expected protein sequence. Search was filtered to a 1% protein FDR as set in the Byonic parameters with the final results filtered to remove glycopeptide assignments with Byonic score below 300 [double the cut off score suggested by Lee et al⁴⁴] to remove low quality glycopeptide assignments. Data are available via ProteomeXchange with identifier PXD019163.

ELISA

Antibody binding to coronavirus S or RBD proteins was tested by ELISA. 96-well Maxisorp plates (Thermo Fisher) were coated overnight at 4°C with 2_μg/mL recombinant S or RBD proteins. After blocking with 1% FCS in PBS, duplicate wells of serially diluted plasma were added and incubated for two hours at room temperature. Plates were washed prior to incubation with 1:20000 dilution of HRP-conjugated anti-human IgG (Sigma) for 1 hour at room temperature. Plates were washed and developed using TMB substrate (Sigma), stopped using sulphuric acid and read at 450nm. Endpoint titres were calculated as the reciprocal serum dilution giving signal 2x background using a fitted curve (4 parameter log regression).

ACE2-RBD inhibition ELISA

An ELISA was performed to measure the ability of plasma antibodies to block interaction between recombinant human ACE2 and RBD proteins. 96-well Maxisorp plates (Thermo Fisher) were coated overnight at 4°C with 8 μg/ml of recombinant RBD protein in carbonate-bicarbonate coating buffer (Sigma). After blocking with PBS containing 1% BSA, duplicate wells of serially diluted plasma (1:25 to 1:1600) were added and incubated for 1 hour at room temperature. Plates were then incubated with 1.5 μg/ml of biotinylated recombinant ACE2 protein for 1 hour at room temperature followed by incubation with HRP-conjugated streptavidin (Thermo Fisher Scientific) for 1 hour at room temperature. Plates were developed with TMB substrate (Sigma), stopped with 0.15 M sulphuric acid and read at 450 nm.

Microneutralisation Assay

SARS-CoV-2 isolate CoV/Australia/VIC01/2020⁴⁵ was passaged in Vero cells and stored at −8°C. Plasma was heat-inactivated at 56°C for 30 min. Plasma was serially-diluted 1:20 to 1:10240 before addition of 100 TCID₅₀ of SARS-CoV-2 in MEM/0.5% BSA and incubation at room temperature for 1 hour. Residual virus infectivity in the plasma/virus mixtures was assessed in quadruplicate wells of Vero cells incubated in serum-free media containing 1 μg/ml TPCK trypsin at 37°C/5% CO2; viral cytopathic effect was read on day 5. The neutralising antibody titre is calculated using the Reed/Muench method as previously described^21,22.

Flow cytometric detection of SARS-CoV-2 reactive B cells

Probes for delineating SARS-CoV-2 S-specific B cells within cryopreserved human PBMC were generated by sequential addition of streptavidin-PE (Thermofisher) to trimeric S protein biotinylated using recombinant Bir-A (Avidity). Biotinylated SARS-CoV RBD was similarly conjugated to streptavidin-BV421 (BD). SARS-CoV-2 RBD protein was directly labelled to APC using an APC Conjugation Lightning-link kit (Abcam). Cells were stained with Aqua viability dye (Thermofisher). Monoclonal antibodies for surface staining included: CD19-ECD (J3-119) (Beckman Coulter), CD20 Alexa700 (2H7), IgM-BUV395 (G20-127), CD21-BUV737 (B-ly4), IgD-Cy7PE (IA6-2), IgG-BV786 (G18-145) (BD), CD14-BV510 (M5E2), CD3-BV510 (OKT3), CD8a-BV510 (RPA-T8), CD16-BV510 (3G8), CD10-BV510 (HI10a), CD27-BV605 (O323) (Biolegend)._Cells were washed, fixed with 1% formaldehyde (Polysciences) and acquired on a BD LSR Fortessa or BD Aria II.

Flow cytometric detection of antigen-specific cTFH and CD4 T cells

Cryopreserved human PBMC were thawed and rested for four hours at 37°C. Cells were cultured in 96-well plates at 1×10⁶ cells/well and stimulated for 20 hours with 5μg/mL of protein (BSA, SARS-CoV-2 S, SARS-CoV-2 RBD, HKU1 S). Selected donors were also stimulated with SEB (5μg/mL) as a positive control. Following stimulation, cells were washed, stained with Live/dead Blue viability dye (ThermoFisher), and a cocktail of monoclonal antibodies: CD27 BUV737 (L128), CCR7 Alexa700 (150503), CD45RA PeCy7 (HI100), CD20 BUV805 (2H7), CD14 BUV395 (MOP9) (BD Biosciences), CD3 BV510 (SK7), CD4 BV605 (RPA-T4), CD8 BV650 (RPA-T8), CD25 APC (BC96), OX-40 PerCP-Cy5.5 (ACT35), PD-1 BV421 (EH12.2H7), CCR6 BV785 (G034E3), CXCR3 Pe-Dazzle594 (G02H57) (Biolegend), and CXCR5 PE (MU5UBEE, ThermoFisher). Cells were washed, fixed with 1% formaldehyde and acquired on a BD LSR Fortessa using BD FACS Diva.

Statistical Analyses

Grouped data are generally presented as median +/- IQR, with groups compared by Wilcoxon or Mann-Whitney U tests using Prism 8.0 (Graphpad). Pairwise correlations were assessed using Spearmans tests in Prism 8.0 (Graphpad). A multiple linear regression was used to determine which factors can be used to predict the values of microneutralization across 41 patients. A backward model selection method was used by first fitting a model with all variables of interest, and gradually removing one variable with the least significant p value. For each step, the nested F test was used to compare the models (ie: if the removed variable contributed significantly to the fit). This procedure was stopped when a model with only significant predictors was obtained. Confirmatory forward selection methods were also employed, arriving at the same final model. This analysis was performed using the lm function in R (v3.6.3).

Spearman correlation matrix was calculated using the rcorr function in R (v3.6.3). Principal component analysis was performed in R (v3.6.3) using the princomp function by first scaling the variables to have a unit variance. Throughout the manuscript, significance was defined as p<0.05.